Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardio Panel To Review Cardica’s Anastomotic Connector, Get CoA Update

This article was originally published in The Gray Sheet

Executive Summary

Cardica, Inc.'s PAS-Port coronary proximal anastomosis device will be reviewed by FDA's Circulatory System Devices Panel April 22

You may also be interested in...



Drug Safety Oversight Initiatives Spur CDRH Postmarket Soul-Searching

The recent spotlight on drug safety is prompting FDA's Center for Devices & Radiological Health to re-examine its regulatory approach to devices

Drug Safety Oversight Initiatives Spur CDRH Postmarket Soul-Searching

The recent spotlight on drug safety is prompting FDA's Center for Devices & Radiological Health to re-examine its regulatory approach to devices

MDUFMA Retains Center Stage In FY ’05, With Postmarket In Supporting Role

CDRH Director Dan Schultz, MD, plans to preserve the strategic framework his predecessor envisioned for the device center

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel